(Q35788989)

10 August 2017

title

Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation (English)

1 reference

10 August 2017

1 reference

Dominique P Germain

15

0 references

Alberto Ortiz

object named as

Alberto Ortiz

2

0 references

David G Warnock

1

object named as

David G Warnock

1 reference

10 August 2017

13

Einar Svarstad

1 reference

10 August 2017

4

Gabor E Linthorst

1 reference

10 August 2017

16

Christoph Wanner

1 reference

10 August 2017

Michael Mauer

3

1 reference

10 August 2017

João P Oliveira

5

1 reference

10 August 2017

Andreas L Serra

6

1 reference

10 August 2017

László Maródi

7

1 reference

10 August 2017

Renzo Mignani

8

1 reference

10 August 2017

Bojan Vujkovac

9

1 reference

10 August 2017

Dana Beitner-Johnson

10

1 reference

10 August 2017

Roberta Lemay

11

1 reference

10 August 2017

J Alexander Cole

12

1 reference

10 August 2017

Stephen Waldek

14

1 reference

10 August 2017

Fabry Registry

17

1 reference

10 August 2017

language of work or name

English

0 references

publication date

29 July 2011

1 reference

Nephrology Dialysis Transplantation

10 August 2017

published in

1 reference

10 August 2017

volume

27

1 reference

10 August 2017

issue

3

1 reference

10 August 2017

page(s)

1042-1049

1 reference

Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry

10 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3289896

Dialysis and transplantation in Fabry disease: indications for enzyme replacement therapy.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3289896

Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3289896

Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN).

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3289896

A new equation to estimate glomerular filtration rate

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3289896

Agalsidase alfa and kidney dysfunction in Fabry disease.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3289896

Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3289896

Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3289896

Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3289896

Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3289896

Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3289896

High incidence of later-onset fabry disease revealed by newborn screening

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3289896

Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3289896

Longitudinal studies on the rate of decline in renal function with age.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3289896

Early renal changes in hemizygous and heterozygous patients with Fabry's disease

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3289896

Therapeutic goals in the treatment of Fabry disease.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3289896

Enzyme replacement therapy and Fabry nephropathy

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3289896

End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3289896

Nephropathy in Fabry disease: the importance of early diagnosis and testing in high-risk populations

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3289896

Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3289896

Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3289896

Assessing kidney function--measured and estimated glomerular filtration rate

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3289896

Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3289896

25 September 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR420

Kidney biopsy findings in heterozygous Fabry disease females with early nephropathy

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1093%2FNDT%2FGFR420

Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype

21 January 2018

1 reference

12 December 2020

Clinical benefit of enzyme replacement therapy in Fabry disease

1 reference

12 December 2020

Agalsidase-beta therapy for advanced Fabry disease: a randomized trial

1 reference

12 December 2020

Antiproteinuric Therapy and Fabry Nephropathy: Sustained Reduction of Proteinuria in Patients Receiving Enzyme Replacement Therapy with Agalsidase-beta

1 reference

12 December 2020

Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria

1 reference

12 December 2020

Enzyme replacement therapy for Fabry's disease

1 reference

12 December 2020

Identifiers

DOI

10.1093/NDT/GFR420

1 reference

10 August 2017

1 reference

10 August 2017

1 reference